Microbot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Microbot Medical (Nasdaq: MBOT) will present commercial progress supporting the Full Market Release (FMR) of the LIBERTY Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference.

The live webcast is April 15, 2026 at 10:15 a.m. ET; management will discuss growth strategy, physician radiation mitigation, staffing benefits, and offer one-on-one investor meetings.

News Market Reaction – MBOT

+3.40%

12 alerts

+3.40% Session close to close

+2.0% Peak Tracked

-6.1% Trough Tracked

$167.90M Market Cap

0.8x Rel. Volume

In the Apr 14 session, MBOT gained 3.40%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.0% during that session. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement emphasizes Microbot Medical’s recent commercial achievements supporting the Full M...

Analysis

This announcement emphasizes Microbot Medical’s recent commercial achievements supporting the Full Market Release of the LIBERTY® endovascular robotic system, showcased at the Needham healthcare conference. It follows a series of updates on FDA clearance, pivotal study publication, and the transition from limited to full U.S. market release. Investors may monitor how conference outreach, institutional meetings, and the active at-the-market program of up to $39,230,691 translate into adoption, revenue, and future financing activity.

Key Figures

ATM offering size: $39,230,691 Shares outstanding: 67,158,044 shares As-adjusted shares: 83,851,955 shares +5 more

8 metrics

ATM offering size $39,230,691 Aggregate capacity under at-the-market program per 424B5

Shares outstanding 67,158,044 shares Common shares outstanding as of Dec 31, 2025

As-adjusted shares 83,851,955 shares Assumes sale of ATM shares at illustrative price

ATM shares assumed 16,693,911 shares Shares assumed sold at $2.35 in prospectus illustration

Illustrative share price $2.35 Price used in ATM prospectus example (Apr 8, 2026 close)

Sales agent commission 3.0% H.C. Wainwright fee on gross ATM proceeds

Shelf expenses $25,000.00 Total issuance and distribution expenses in S-3/A

SEC registration fee $404.02 SEC fee included in S-3/A expenses

Historical Context

5 past events · Latest: Apr 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 13	Full market release	Positive	-9.3%	Announced U.S. full market release of LIBERTY after limited rollout.
Mar 26	Clinical usage update	Positive	+3.6%	Emory completed first robotic PAE and Y-90 mapping using LIBERTY.
Mar 24	Pivotal study publication	Positive	-0.8%	ACCESS-PVI pivotal study for LIBERTY published in peer-reviewed journal.
Mar 17	Conference participation	Positive	+1.1%	Roth Conference presentation on LIBERTY commercialization and FMR plans.
Mar 10	Conference participation	Positive	+2.9%	Oppenheimer conference appearance outlining LIBERTY LMR progress and growth drivers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has focused on LIBERTY’s commercialization and clinical validation. Positive milestones such as FDA clearance, pivotal study publication and market expansion have seen mixed reactions, including a -9.27% drop on the prior day’s full market release news, indicating that strong operational updates have not always translated into sustained price strength.

Recent Company History

Over the past month, Microbot Medical has advanced the LIBERTY® system from limited to full U.S. market release, highlighted by the Apr 13 FMR announcement and earlier clinical milestones at Emory and the ACCESS-PVI pivotal study publication. Multiple conference appearances (Oppenheimer, Roth, and now Needham) have been used to showcase commercialization progress and safety advantages. Today’s conference-focused news builds directly on the full market release narrative introduced in recent 8-K filings and press releases.

Key Terms

endovascular, at-the-market offering, shelf registration statement, form s-3, +4 more

8 terms

endovascular medical

"LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures"

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

at-the-market offering financial

"proposes an at-the-market offering to sell up to $39,230,691 aggregate offering price"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

shelf registration statement regulatory

"These sales will be made under a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3, using a prospectus and a new prospectus supplement"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"using a prospectus and a new prospectus supplement filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

sec registration fee regulatory

"Listed issuance and distribution expenses total $25,000.00, including an SEC registration fee of $404.02"

A SEC registration fee is the charge a company pays to the U.S. Securities and Exchange Commission when it registers securities for sale to the public. Think of it like a filing fee for a permit: the fee is calculated from the size of the offering, slightly reduces the cash available from the sale, and signals that the company is following regulatory steps investors expect for transparency and legal compliance.

rule 473(b) regulatory

"The amendment adds Rule 473(b) language for automatic effectiveness 20 days following filing"

Rule 473(b) is an SEC securities regulation that clarifies when written or graphic communications count as a prospectus for registered offerings, especially when they incorporate by reference material from a registration statement. For investors, that matters because it determines what information must be delivered or made available before a sale, and when liability for incomplete or misleading disclosures can attach—think of it as a rule that sets the ground‑truth for what written materials legally become part of the official offering documents.

pivotal study medical

"ACCESS PVI pivotal study in the Journal of Vascular and Interventional Radiology"

A pivotal study is a large, definitive clinical trial designed to show whether a medical product works and is safe enough for regulators to approve and for doctors to use. Think of it as the final exam that determines whether a drug or device moves from testing into the market; its results can dramatically change a company’s approval chances, future sales prospects, and therefore its stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The presentation will be webcast live on April 15 at 10:15 a.m. ET. Continued Engagement with Healthcare Institutions Reflects Rising Momentum

HINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16^th. Harel Gadot, CEO, President & Chairman of Microbot Medical, will be presenting live at 10:15 a.m. ET on Wednesday, April 15, 2026. Mr. Gadot, along with other of Microbot’s senior executives, will provide an overview of the Company and its strategic positioning, growth opportunities, and ability to address markets with multiple unmet needs, including physician radiation risks, physical strain and staffing issues.

The presentation will be webcast live and may be accessed via the ‘Investors’ section on Microbot Medical’s website at https://ir.microbotmedical.com/. Additionally, the Microbot Medical team will meet with healthcare-focused institutional investors through a series of pre-scheduled one-on-one meetings. Interested parties should reach out to their Needham sales representatives or contact ir@microbotmedical.com to schedule a one-on-one meeting.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company recently completed the limited market release of the LIBERTY system in the U.S. and commenced its full market release in the U.S. earlier this week at the Society of Interventional Radiology (SIR) Annual Scientific Meeting.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

When will Microbot Medical (MBOT) present at the Needham Virtual Healthcare Conference in April 2026?

Microbot Medical will present live on April 15, 2026 at 10:15 a.m. ET. According to Microbot Medical, the presentation will be webcast and accessible via the Investors section on the company website for remote viewing and replay.

What will Microbot Medical (MBOT) discuss about the LIBERTY system during the April 15, 2026 presentation?

The company will highlight recent commercial achievements and the Full Market Release of LIBERTY. According to Microbot Medical, management will cover strategic positioning, growth opportunities, and clinical benefits such as reduced radiation and physical strain for physicians.

How can investors access the Microbot Medical (MBOT) webcast and request one-on-one meetings at Needham 2026?

Investors can access the live webcast via the Investors section on Microbot Medical’s website. According to Microbot Medical, interested investors should contact Needham sales reps or email ir@microbotmedical.com to schedule pre-arranged one-on-one meetings.

What is the regulatory status of the LIBERTY endovascular robotic system mentioned by Microbot Medical (MBOT)?

LIBERTY is FDA cleared as a single-use, remotely operated robotic system for peripheral endovascular procedures. According to Microbot Medical, the system is designed for precise vascular navigation and aims to reduce radiation exposure and operator strain.

When did Microbot Medical (MBOT) commence full market release of the LIBERTY system in the U.S.?

Microbot Medical commenced the U.S. full market release earlier in the week of April 14, 2026 at the SIR Annual Scientific Meeting. According to Microbot Medical, this followed a prior limited market release and signals broader commercial rollout plans.